HPLC + MS verified · Batch PX-2026-0142 live
Precursor
Precursor
Home/Journal/Field guide
Field guide

Peptide storage: a practical guide to reconstitution and drift.

·7 min read

Lyophilized peptides are stable. Reconstituted peptides aren't. That sentence is the whole article in compressed form, but the details of why and by how much matter for anyone running an experiment that depends on dose accuracy.

Lyophilized — the stable state

Freeze-drying removes water from the peptide preparation under vacuum, leaving a porous solid. Without water, the chemistry that breaks peptides apart — hydrolysis, oxidation, deamidation — slows by orders of magnitude. The Manning, Patel & Borchardt 1989 review of protein pharmaceutical stability is still the canonical reference for the underlying degradation pathways [1]; Wang's 1999 review on lyophilized stability quantifies the kinetics [2].

Practical implication: lyophilized peptides at −20°C are stable for 3+ years; at 4°C, 24+ months; at room temperature in the dark, 12+ months for most sequences. The exceptions are peptides with labile residues (free cysteines, methionines prone to oxidation, asparagines prone to deamidation), which degrade faster regardless of temperature.

Reconstitution changes the math

The moment you add water, you reset the stability clock. Reconstituted peptides at 4°C are typically stable for 30–60 days, depending on sequence and pH. At room temperature, days to a week. Frozen reconstituted peptides last longer but introduce a new variable: freeze-thaw cycles.

Each freeze-thaw cycle physically stresses the peptide. Ice crystal formation can denature secondary structure; concentrated solute pockets during freezing can drive aggregation; the thaw introduces local heating that accelerates hydrolysis. Multiple cycles compound. Best practice: aliquot before freezing so you only thaw what you need.

Bacteriostatic water vs sterile water

Bacteriostatic water for injection (BWFI) contains 0.9% benzyl alcohol as a preservative, which prevents microbial growth in multi-dose preparations and extends usable life of a reconstituted vial from days to weeks. The trade-off: benzyl alcohol can interfere with assays sensitive to small organic molecules (some HPLC methods, some receptor-binding studies), so for sensitive in-vitro work, sterile water is cleaner. For most research use cases involving intact-vial dosing over a multi-week window, BWFI is the practical choice.

What actually degrades peptides

  • Temperature — the rate of nearly every degradation reaction roughly doubles per 10°C increase. Cold storage isn't optional for reconstituted peptides; it's required.
  • Light — UV exposure drives oxidation of methionine, cysteine, and tryptophan residues. Amber vials or light-protected storage matters for sensitive sequences.
  • Oxygen — atmospheric oxygen oxidizes the same residues. Properly sealed vials with minimal headspace are more stable than partially-used vials.
  • pH — most peptides are most stable at slightly acidic pH (4–6). The further from that range the diluent, the faster the degradation.
  • Adsorption — peptides at low concentrations stick to glass and plastic surfaces. Working concentrations matter; if you're below ~10 μg/mL, surface adsorption can meaningfully reduce active drug in solution.

What we recommend

Keep lyophilized vials at 2–8°C until you're ready to reconstitute. Reconstitute with bacteriostatic water unless your assay requires sterile. Aliquot once if you're going to freeze. Avoid freeze-thaw cycles. Use within 30 days at 2–8°C, less if the sequence has labile residues.

If you're working at the edge of detection or need maximal dose accuracy, factor in 5–10% loss per month at 4°C as a planning assumption. The published shelf-life numbers represent the date by which a representative sequence still meets specification — they aren't a promise of zero degradation up to that date.

Citations
  1. [1]Manning MC, Patel K, Borchardt RT. Stability of Protein Pharmaceuticals. Pharm Res 1989.
  2. [2]Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 1999.
Research use only. Not for diagnostic, therapeutic, or human-consumption use. Citations are sourced from published literature and regulatory documents. We disclose no financial conflicts with any cited author or organization.